Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of keratinization disorders recognized by abnormal skin scaling over the entire body and classified as non-syndromic and syndromic forms of ichthyosis. ABCA12, ALOX12B, ALOXE3, CASP14, CERS3, CYP4F22, LIPN, NIPAL4, PNPLA1, SDR9C7, SLC27A4, and TGM1 are the twelve genes known to be involved with ARCI; at least 15% of affected families do not have pathogenic variants in any of the known genes. 60% to 70% of the patients have severe symptoms such as collodion membrane at birth. The two main phenotypes are lamellar ichthyosis and congenital ichthyosiform erythroderma; however, phenotypic overlap can occur in the same patient or patients from the same family. Some patient exhibits nonlamellar, non-erythrodermic ichthyosis. It also includes harlequin ichthyosis, acral self-healing collodion baby, self-healing collodion baby, and bathing suit ichthyosis.
- The estimated prevalence at birth of 1 per 100 000 population for lamellar ichthyosis and 1 per 200 000 population for congenital ichthyosiform erythroderma in the U.S.
Thelansis’s “Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Recessive Congenital Ichthyosis (ARCI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Autosomal Recessive Congenital Ichthyosis (ARCI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Autosomal Recessive Congenital Ichthyosis (ARCI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
